Current evidence suggests that the application of immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 and the combination of immunization and standard chemotherapy significantly prolong the survival of tumor patients (39). Here, CTLA4 is linked to neoplasm.